Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 68 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in... September 26, 2024 Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer May 21, 2024 Does Eating Processed Meat Increase Your Risk for Cancer? September 19, 2023 Bride Diagnosed with Stage IV Triple-Negative Breast Cancer 6 Months Before... June 17, 2020 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... Coping with Grief: An Interview with Author Rebecca Munn
